Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03462927 · ClinicalTrials.gov registry record · Phase 2
A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream
A Phase 2 study, sponsored by MC2 Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT03462927: Completed Phase 2 study, sponsored by MC2 Therapeutics.
NCT03462927 is a Phase 2 study that has completed, run by MC2 Therapeutics. The registered enrollment target is 63 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03462927, a Phase 2 study, has completed, sponsored by MC2 Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
This is a phase 2, randomised, open-label, parallel-group, multicentre trial in which MC2-01 cream and calcipotriene \[CAL\]/betamethasone \[BDP\] ointment (comparator) is investigated in subjects with clinically diagnosed extensive psoriasis vulgaris.
Primary Outcome
Geometric Mean for Maximum Plasma Concentration \[Cmax\] for the active ingredient Calcipotriene. Plasma concentration was measured at the following timepoints: pre-dose, 30 min, 1, 2, 3, 5 and 7 hours post-dose
Interventions
- DRUG MC2-01 Cream
- DRUG CAL/BDP combination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2018-02-08 |
| Est. Completion | 2018-08-04 |
| Phase | Phase 2 |
What the finished NCT03462927 record still lists
NCT03462927 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 2 interventions - of which MC2-01 Cream is the first listed.
NCT03462927 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03462927 about?
NCT03462927 is a clinical study titled "A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream". This is a phase 2, randomised, open-label, parallel-group, multicentre trial in which MC2-01 cream and calcipotriene \[CAL\]/betamethasone \[BDP\] ointment (comparator) is investigated in subjects with clinically diagnosed extensive psoriasis vulgaris.
What is the current status of trial NCT03462927?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2018-02-08. Estimated completion is 2018-08-04.
What interventions are being tested in trial NCT03462927?
The interventions under investigation include: MC2-01 Cream (DRUG), CAL/BDP combination (DRUG).
Who is sponsoring clinical trial NCT03462927?
This trial is sponsored by MC2 Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03462927's enrollment target sits among peer trials
63 1009th of 2000 higher than 985 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI